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Abstract
Background In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI out-
comes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing–remitting MS. Here, 
we assess efficacy and safety of alemtuzumab over 12 years in CAMMS223 patients who enrolled in the CAMMS03409 
extension (NCT00930553), with available follow-up through the subsequent TOPAZ extension (NCT02255656).
Methods In CAMMS223, patients received 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days); 
22% received a third course. In the open-label, nonrandomized extensions, patients could receive as-needed additional 
alemtuzumab or other disease-modifying therapies.
Results Of 108 alemtuzumab-treated patients in CAMMS223, 60 entered the CAMMS03409 extension; 33% received a total 
of 2 alemtuzumab courses, and 73% received no more than 3 courses through Year 12. Over 12 years, annualized relapse rate 
was 0.09, 71% of patients had stable or improved Expanded Disability Status Scale scores, and 69% were free of 6-month 
confirmed disability worsening. In Year 12, 73% of patients were free of MRI disease activity. Cumulatively throughout the 
extensions (Years 7–12), 34% of patients had no evidence of disease activity. Adverse event (AE) incidence declined through 
Year 12. Infusion-associated reactions peaked at first course and declined thereafter. Cumulative thyroid AE incidence was 
50%; one immune thrombocytopenia event occurred, and there were no autoimmune nephropathy cases.
Conclusions Alemtuzumab efficacy was maintained over 12 years in CAMMS223 patients, with 73% receiving no more than 
three courses. The safety profile in this cohort was consistent with other alemtuzumab clinical trials.
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Introduction
Multiple sclerosis (MS) is a lifelong potentially debilitating 
disorder of the central nervous system that usually evolves 
over several decades and requires long-term treatment to 
slow the accumulation of disability and disease progres-
sion [1–3]. Alemtuzumab  (LEMTRADA®; Sanofi, Cam-
bridge, MA, USA) is an anti-CD52 humanized monoclonal 
antibody approved for the treatment of relapsing–remitting 
MS (RRMS) [4, 5]. In a 3-year phase 2 trial (CAMMS223; 
NCT00050778), patients with active RRMS who were treat-
ment-naive at baseline demonstrated significantly greater 
improvements in clinical and radiological outcomes with 
alemtuzumab compared with subcutaneous interferon beta-
1a (SC IFNB-1a;  Rebif®; EMD Serono Inc., Rockland, MA, 
USA) [6]. Alemtuzumab also demonstrated significant effi-
cacy versus SC IFNB-1a over 2 years in phase 3 clinical 
trials (CARE-MS I [NCT00530348] and II [NCT00548405]) 
[7, 8], and efficacy was maintained in two consecutive exten-
sion studies (CAMMS03409 [NCT00930553]; TOPAZ 
[NCT02255656]) [9–13]. Adverse events (AEs) associ-
ated with alemtuzumab in clinical trials and post-marketing 
experience include infusion-associated reactions (IARs), 
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increased frequency of infection and the potential for 
opportunistic infections, secondary autoimmunity (thyroid 
disorders, immune thrombocytopenia [ITP], nephropa-
thies, autoimmune cytopenias, autoimmune hepatitis, and 
other less common autoimmune events), acute acalculous 
cholecystitis, and cardiovascular and pulmonary events pos-
sibly related to infusion [4, 6–11, 14–16].
Alemtuzumab-treated patients from the CAMMS223 
study could participate in a follow-up period of 2.5 additional 
years on average, and then enroll in the CAMMS03409 and 
subsequent TOPAZ extension studies. This long-term fol-
low-up period allowed an assessment of efficacy and safety 
outcomes in alemtuzumab-treated CAMMS223 patients over 
12 years.
Methods
Study design, participants, and procedures
The study designs of the phase 2 CAMMS223 trial, and the 
CAMMS03409 and TOPAZ extension studies have previ-
ously been described [6, 9–13, 17].
CAMMS223 study
CAMMS223 was an active-controlled, rater-blinded, head-
to-head, 3-year trial of treatment-naive patients with early, 
active RRMS (Fig. 1). Early, active RRMS was defined as 
patients with an onset of symptoms ≤ 3 years prior to study 
entry, Expanded Disability Status Scale score (EDSS) 
of ≤ 3.0, ≥ 2 clinical episodes in the previous 2  years, 
and ≥ 1 gadolinium (Gd)-enhancing lesion on cranial mag-
netic resonance imaging (MRI). Patients were randomized 
to either alemtuzumab (two courses of 12 or 24 mg/day IV 
on 5 consecutive days at baseline and on 3 consecutive days 
12 months later), or SC IFNB-1a (44 µg 3 times per week). 
A third course of alemtuzumab could be given ≥ 12 months 
after the last course at the treating physicians’ discretion if 
the CD4+ T-cell count was ≥ 100 × 106 cells per liter [6]. 
Approximately 33 months from the study start, alemtuzumab 
dosing was suspended after three cases of ITP were reported, 
including one fatality, but efficacy and safety evaluations 
proceeded as planned [6].
CAMMS223 follow‑up
After completion of the core CAMMS223 study, patients 
were invited to participate in an extended follow-up [17] 
(Fig. 1), the average duration of which was 2.5 years (stand-
ard deviation [SD], 1.0). In consultation with the investigator, 
after the dose suspension was lifted, patients had the option 
to receive additional alemtuzumab courses (12 mg/day on 3 
consecutive days ≥ 12 months apart) during this follow-up 
period: two additional courses of alemtuzumab (not contin-
gent upon evidence of disease activity) or alemtuzumab as 
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other (4); physician decision (1); withdrawal by patient (1)
Discontinued during the CAMMS03409/TOPAZ
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Long-term follow-up
cohort: enrolled in the
CAMMS03409 extension
(n = 60)c
Completed
Year 12
(n = 54)
CAMMS03409/TOPAZ Extension Studiesa
CAMMS223
Follow-upa
CAMMS223
Core Study
Approximate timing of dosing suspension
Fig. 1  Study design and patient disposition of the CAMMS223 long-
term follow-up cohort. Schematic of the CAMMS223 long-term fol-
low-up cohort participation (N = 60) from the core CAMMS223 trial 
through the CAMMS03409 extension study and TOPAZ. For each 
patient of the long-term follow-up cohort, data were analyzed from 
enrollment in the CAMMS223 core study until end of Year 12. aThe 
timing of the CAMMS223 follow-up period, CAMMS03409 exten-
sion study, and TOPAZ extension study was variable, with most 
patients being followed up for 3 years, 4 years, and 2 years (to date), 
respectively, in each study; bPatients had the option to receive addi-
tional alemtuzumab courses in the CAMMS223 follow-up period 
after the lifting of the dose suspension (in effect between 2005 
and 2008); cOne patient was discontinued from the core CAMMS223 
study and re-enrolled into the extension study. AE adverse event, 
C course, DMT disease-modifying therapy, Y year
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needed for predefined disease activity (≥ 1 protocol-defined 
relapse or ≥ 2 Gd-enhancing or new/enlarging T2 hyperin-
tense MRI lesions within the previous year).
CAMMS03409 extension study
On completion of this extended follow-up from the 
CAMMS223 study, patients were then eligible to enroll in 
the CAMMS03409 extension study and receive additional 
courses of alemtuzumab as needed for predefined disease 
activity at the investigator’s discretion [9–11] (Fig. 1).
TOPAZ extension study
Thereafter, further follow-up was available beyond 
CAMMS03409 as part of the TOPAZ extension study, where 
patients could again receive additional alemtuzumab at the 
discretion of the investigator (not contingent upon evidence 
of disease activity) [12, 13] (Fig. 1).
Treatment with other approved disease-modifying thera-
pies (DMTs) was permitted at the investigator’s discretion 
during the CAMMS223 trial and its extended follow-up 
period, the CAMMS03409 extension, as well as the TOPAZ 
extension studies. The studies were conducted in accordance 
with the ethical principles outlined in the Declaration of 
Helsinki. All procedures were approved by local institutional 
ethics review boards of participating sites, and patients pro-
vided written informed consent.
Assessments
Clinical efficacy assessments included annualized relapse 
rate (ARR), mean change from core study baseline in EDSS 
score, and proportions of patients with EDSS score stability 
(≤ 0.5-point change in either direction), improvement (≥ 1.0-
point decrease), or worsening (≥ 1.0-point increase). Con-
firmed disability worsening (CDW) was defined as ≥ 1.0-
point EDSS increase (or ≥ 1.5 points if baseline EDSS = 0) 
confirmed over 6 months, and confirmed disability improve-
ment (CDI) was defined as ≥ 1.0-point EDSS decrease from 
baseline confirmed over 6 months (assessed only in patients 
with baseline EDSS ≥ 2.0).
MRI assessments included the proportions of patients free 
from new MRI lesions (new Gd-enhancing T1, new/enlarg-
ing T2 hyperintense, or new non-enhancing T1 hypointense 
lesions). Patients free of MRI disease activity were defined 
as having no new Gd-enhancing T1 lesions on current MRI 
or new/enlarging T2 hyperintense lesions since last MRI. 
MRI lesion counts were assessed only from the onset of the 
CAMMS03409 extension study and beyond.
No evidence of disease activity (NEDA) was defined as 
absence of both clinical disease activity (absence of both 
relapses and 6-month CDW) and MRI disease activity 
and was evaluated annually and cumulatively from the 
CAMMS03409 extension study enrollment and onward, 
until end of Year 12.
AEs, serious AEs, and AEs of special interest were 
recorded throughout the studies. IARs were defined as any 
AE with onset during or within 2 days after alemtuzumab 
infusion. Serious AEs were defined as fatal or life threat-
ening, requiring or prolonging inpatient hospitalization, 
disabling, resulting in a congenital anomaly, or requiring 
medical or surgical intervention to influence these outcomes. 
AEs of special interest did not meet criteria for serious AEs 
but were of particular interest in the context of the study; 
these events included autoimmune cytopenias (i.e., ITP, 
autoimmune hemolytic anemia, and autoimmune neutro-
penia), glomerulonephritis, other autoimmune disorders, 
pregnancy, cervical dysplasia, opportunistic infections, and 
malignancies. Monitoring for autoimmune AEs included 
monthly complete blood cell count assessments and renal 
evaluations, and quarterly thyroid function testing for at least 
4 years from the administration of the last alemtuzumab 
dose.
To examine the individual patients’ clinical course of 
MS at the time of study discontinuation, efficacy and safety 
outcomes were evaluated in alemtuzumab-treated patients 
from the CAMMS223 core study who did not enroll in the 
CAMMS03409 extension study.
Statistics
This analysis included all available data (without imputa-
tion) for patients who received 12 mg/day alemtuzumab in 
the CAMMS223 core trial, enrolled in the CAMMS03409 
extension study, with available further follow-up in TOPAZ. 
Patients who received 24 mg/day alemtuzumab in the core 
CAMMS223 study were excluded.
ARR was estimated through negative binomial regres-
sion with robust variance estimation. Proportions of 
patients with 6-month CDW or 6-month CDI events were 
determined with Kaplan–Meier estimates. MRI scans for 
Gd-enhancing lesions were not collected during the core 
CAMMS223 study and its follow-up period; hence, propor-
tions of patients free of new MRI lesions and MRI disease 
activity, as well as proportions of patients with NEDA, were 
assessed from the onset of CAMMS03409 extension study, 
and evaluated annually onward. Proportions of patients with 
sustained NEDA, evaluated cumulatively from the onset of 
CAMMS03409 extension study until end of Year 12, were 
estimated with the Kaplan–Meier method.
Incidences (percentage of patients with ≥ 1 event) of AEs, 
serious AEs, and medical events of interest were reported 
annually.
In patients who withdrew prior to enrolling in the 
CAMMS03409 extension study, relapse rates and AEs 
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were evaluated from core CAMMS223 study baseline 
(Year 0) to the time of discontinuation (Year 6). Disability 
outcomes (EDSS scores, 6-month CDW, and 6-month CDI) 
were assessed from core study baseline until the most recent 
EDSS assessment available prior to discontinuation (Year 5).
Results
Patient disposition and additional treatment
Of the 108 patients who received alemtuzumab 12 mg/day 
in the CAMMS223 core study, 60 (56%) enrolled in the 
CAMMS03409 extension study, and had further follow-up 
in TOPAZ; 54 (50%) patients remained on study at Year 12 
(Fig. 1). Of the six patients who discontinued after enrolling 
in the extension study, three withdrew due to physician deci-
sion, two withdrew their consent, and one death occurred 
due to hemorrhagic shock from an accident unrelated to the 
study.
Over 12 years, 20/60 patients (33%) received a total of 
two courses of alemtuzumab, and 39/60 patients (65%) 
received additional courses, with 38%, 15%, 3%, 7%, and 
2% receiving a total of 3, 4, 5, 6, and 7 courses, respec-
tively. One patient (2%) received only one course. Of the 
39 patients who received ≥ 3 alemtuzumab courses, 14 
(36%) received a third course in the core CAMMS223 
study, and 22 (56%) received it in Years 5–6; 3 patients (8%) 
received a third course in Years 7–9. Of the 16 patients who 
received ≥ 4 courses, 12 (75%) received a fourth course in 
Years 6–8, and 4 (25%) in Years 10–12. For most patients 
(57.4%), the reason for additional treatment was not docu-
mented. Among those for whom reasons were known, the 
most common were relapse activity (27.9%), MRI activ-
ity (4.4%), both relapse and MRI activity (8.8%), and both 
relapse and EDSS progression (1.5%). Through 12 years, 
12/60 (20%) patients received other DMTs, most frequently 
interferons and glatiramer acetate.
Efficacy in the long‑term follow‑up cohort
Annually through Year 12, ARR remained low (0.03–0.14). 
The cumulative ARR was 0.09 over 12 years and similar 
to the relapse rate in the core CAMMS223 study (0.08; 
Fig. 2a). At Year 12, 49% of patients showed stable EDSS, 
and 22% showed improved EDSS from core study baseline 
(Fig. 2b). Mean EDSS change from baseline was + 0.33 (SD, 
1.6). Through Year 12, 69% of patients were free of 6-month 
CDW (Fig. 2c), and 53% achieved 6-month CDI (Fig. 2d). 
To determine whether CDI was maintained over 12 years, 
patients who achieved CDI were assessed for subsequent 
CDW. Of the 19 patients who achieved CDI over 12 years, 
17 (89%) had no subsequent CDW.
In each year of the CAMMS03409 and subsequent 
TOPAZ extension studies through Year 12, ≥ 69% of 
patients were free of MRI disease activity, with ≥ 87% hav-
ing no new Gd-enhancing T1 lesions, and ≥ 69% having 
no new/enlarging T2 lesions; ≥ 82% were free of new T1 
hypointense lesions (Fig. 3). Proportions of patients with 
annual NEDA were 63–78% through Year 12 (extension 
Year 1: 78%; extension Year 2: 67%; extension Year 3: 64%; 
extension Year 4: 68%; extension Year 5: 63%; extension 
Year 6: 67%). From the onset of the CAMMS03409 exten-
sion study and until the end of Year 12, 33.9% (95% CI, 
22.0–46.1%) of patients had sustained NEDA (Fig. 4). 
Safety in the long‑term follow‑up cohort
AE incidences in the long-term follow-up cohort over 
12 years are shown in Table 1. Incidence rates of most 
AEs declined in the CAMMS223 follow-up period and 
the CAMMS03409/TOPAZ extensions (Years 4–12) rela-
tive to the core study (Years 1–3). No patients withdrew 
from the extension studies due to AEs. The majority of AEs 
(97%) were mild to moderate. Nine grade 4 events occurred 
through 12 years: one event each of adhesive ileus and dif-
fuse serious peritonitis (both in Year 1 in the same patient), 
two cases of neutropenia (one each in Years 4 and 5), two 
events of generalized rash (both in Year 1 in the same 
patient), and two malignant melanomas (one metastatic) and 
one lymphadenopathy (all in Year 10 in the same patient). 
One death occurred in Year 7 from a hemorrhagic shock due 
to deep left brachial vein damage as a result of an incised 
wound from an accident unrelated to the study.
IARs declined after the first course of alemtuzumab 
(Course 1: 98%; Course 2: 80%; Course 3: 77%; Course 4: 
63%). Of the 12 patients who received Courses 5 and 6, 7 
(58%) reported IARs; no IARs were reported in the 1 patient 
who received Course 7. The most commonly reported IARs 
over 12 years were rash (65%) and headache (58%). In this 
long-term follow-up cohort, there were no reports of acute 
cardiovascular and pulmonary events, such as pulmonary 
alveolar hemorrhage, stroke, myocardial infarction, and 
cervicocephalic arterial dissection occurring shortly after 
initiation of alemtuzumab. Incidence of an ischemic stroke 
and a myocardial infarction was reported in 1 patient over 
12 years, and occurred 1.9 and 1.8 years, respectively, after 
the most recent alemtuzumab dose.
Infection rate was highest during Year 1 (53%) and 
declined thereafter. Serious infections occurred in < 4% 
of patients during each year through Year 12. In 10% of 
patients, the first infection occurred within a year of the most 
recent alemtuzumab dose. There were no cases of Listeria 
monocytogenes or cytomegalovirus infection over 12 years.
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Thyroid AEs peaked in Years 2 and 3 (15% in each), 
and subsequently declined. Five patients had thyroid AEs 
more than 4 years (range 4.0–8.8 years) after the last alem-
tuzumab course (four cases of hyperthyroidism/Graves’ 
disease [three were serious events] and one of Hashimoto’s 
thyroiditis). Over 12 years, there was one case of ITP, 
with an initial onset in Year 4 (16 months after the last 
alemtuzumab dose), which resolved spontaneously without 
treatment; the same patient experienced delayed ITP recur-
rence 8 years after the last alemtuzumab dose, which was 
treated with intravenous steroids and platelet transfusion 
[15]. There were no cases of autoimmune nephropathy 
observed over 12 years. One case of cholecystitis was 
observed in Year 10 and did not meet the defining criteria 
for acute acalculous cholecystitis. Four cases of grade 3/4 
neutropenia were observed over 12 years, which occurred 
11–46 months after the most recent alemtuzumab dose.
Two patients had malignancies; all were melanomas 
and occurred in Year 10 of follow-up. One patient with 
a family history of melanoma had two grade 4 malignant 
melanomas that were deemed by the study investigator to 
be possibly related to study drug. The other patient was 
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Fig. 3  MRI lesion outcomes 
of the CAMMS223 long-term 
follow-up cohort. Propor-
tions of patients free of MRI 
disease activity, and of new 
MRI lesions (Gd-enhancing 
T1, new/enlarging T2 and new 
T1) from Year 7 to Year 12 
(CAMMS03409 extension study 
enrollment until end of Year 
12) in the long-term follow-
up cohort. MRI outcomes 
were assessed annually from 
the CAMMS03409 extension 
study enrollment and onward, 
until end of Year 12. Freedom 
from MRI disease activity was 
defined as the absence of new 
gadolinium-enhancing T1 and 
new/enlarging T2 hyperintense 
lesions. Error bars denote 95% 
CIs. CI confidence interval, Gd 
gadolinium
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diagnosed with grade 2 melanoma in situ (abdomen), con-
sidered unrelated to study drug by the investigator, and 
was resolved by surgical excision.
Efficacy and safety in patients who discontinued 
prior to enrolling in the CAMMS03409 extension
Of the 48 patients who did not enroll in the CAMMS03409 
extension study, 3 discontinued due to AEs, 2 due to lack 
of efficacy, and 1 death occurred due to cardiovascular 
disease [6]. Seventeen patients discontinued due to other 
reasons (including noncompliance with study drug, patient 
withdrawal, lost to follow-up, and physician decision), and 
no reason was provided for 25 patients (Fig. 1). Baseline 
characteristics were similar between patients who discontin-
ued, and those that remained in the study through 12 years 
(Supplementary Table S1). Mean EDSS score in this group 
at the time of discontinuation was similar to the study start 
(1.9 vs. 2.0), and mean number of relapses in the 1–2 years 
prior to study withdrawal ranged from 0.3 to 0.4. At the time 
of withdrawal, cumulative ARR in discontinued patients was 
higher (0.19 in Years 0–6; Supplementary Fig. 1a) than in 
the long-term follow-up cohort (0.09 in Years 0–12; Fig. 2a). 
Disability outcomes in discontinued patients were generally 
consistent with the 12-year follow-up cohort. Over 5 years, 
77% of patients showed stable or improved EDSS from core 
study baseline (Supplementary Fig. 1b). Through Year 5, 
87% of patients remained free of 6-month CDW and 30% 
achieved 6-month CDI (Supplementary Fig. 1c, d). Safety 
findings in patients who discontinued were consistent with 
the long-term follow-up cohort, with AEs occurring most 
frequently in Year 1 (98%) and declining thereafter until 
discontinuation (Year 6). Thyroid AEs peaked at Year 3 
(11.4%), with lower incidences observed through Years 4–6 
(2.9–10.0%; Supplementary Table S2).
Discussion
DMTs are effective in reducing relapses and early disabil-
ity progression in patients with RRMS, but their long-
term efficacy in various stages of MS is largely unknown 
[1]. Findings of our study show that alemtuzumab effi-
cacy on clinical and MRI outcomes was maintained over 
12 years in the long-term follow-up cohort of CAMMS223 
patients who enrolled in the CAMMS03409 and the sub-
sequent TOPAZ extension studies. ARR remained low 
over 12 years (0.09), and 69–85% of patients were free of 
MRI disease activity in each year of the extension stud-
ies. The majority (71%) of alemtuzumab-treated patients 
showed stable or improved disability based on EDSS 
scores through Year 12. Additionally, 34% of patients 
were free of disease activity over 6 years, from the onset 
of the CAMMS03409 extension study through end of 
Year 12, suggesting remission. Importantly, these results 
were achieved with 33% of patients receiving a total of 2 
courses of alemtuzumab, and 73% receiving no more than 
three courses over 12 years. These results are consistent 
with the 9-year analysis of the phase 3 CARE-MS stud-
ies, in which improvements were seen in clinical, MRI, 
and disability outcomes in alemtuzumab-treated RRMS 
patients [12, 13].
Patient retention in long-term trials over multiple years 
can be challenging; personal reasons or fatigue due to study 
burden can contribute to high discontinuation rates [18]. 
In our study, 50% of patients originally randomized to the 
core CAMMS223 trial remained on study through 12 years. 
This is higher than the retention rate reported for patients 
on fingolimod in the LONGTERMS extension study, where 
41% of the 3168 patients enrolled have received more than 
2 years of treatment; only a small cohort of 25 patients has 
received treatment for up to 10 years [19]. While higher 
retention rates (56–71%) have been reported in extension 
studies with other DMTs such as cladribine, natalizumab, 
and ocrelizumab, to date these have been over a shorter fol-
low-up period ranging from 4 to 5 years [20–22].
The most common reason for discontinuation in our 
study was noncompliance with study drug, and nearly all 
patients who discontinued for this reason did so during the 
CAMMS223 core trial. Other reasons were likely related 
to the length of the trial, and included patient withdrawal, 
failure to maintain follow-up, and physician decision; 23% 
of the originally CAMMS223 randomized cohort withdrew 
with no reason provided. Notably, discontinuations due to 
documented lack of efficacy or presence of AEs were low. In 
that respect, baseline characteristics of CAMMS223 patients 
who discontinued prior to enrollment in the CAMMS03409 
extension were similar to the long-term follow-up cohort 
who remained on study through 12 years. Compared with the 
12-year cohort, patients who discontinued had higher ARR 
at the time of study withdrawal (0.09 vs. 0.19). However, 
other clinical efficacy outcomes up to the time of discontinu-
ation were largely similar between the two cohorts, arguing 
against a selection bias in favor of continuation in patients 
who perceived themselves to be benefitting from treatment 
or withdrawal in others who may have been dissatisfied with 
their treatment.
The accumulation of impairment and disability over 
the long-term has a profound negative impact on MS 
patients. Thus, reducing disease progression and improving 
preexisting disability is an important treatment goal. Our 
results showed that 71% of alemtuzumab-treated patients had 
improved or stable EDSS scores over 12 years, and the aver-
age EDSS score change from baseline to Year 12 was + 0.33. 
Nearly 70% of patients were free of 6-month CDW, and 53% 
attained 6-month CDI. Of those that achieved CDI at any 
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time during the course of the study, 89% were free from 
CDW, indicating that improvement in preexisting disability 
was consistent and generally maintained over 12 years.
Most patients (73%) in this 12-year cohort required no 
more than one additional alemtuzumab course beyond the 
initial two courses as prescribed in the protocol. Patients most 
frequently received additional treatment with alemtuzumab in 
the later years, providing further support for maintenance of 
efficacy over the long-term. Although the exact mechanism 
of action is not fully known, the sustained treatment effect 
with alemtuzumab may be the result of immunomodulatory 
effects due to the selective depletion of circulating T and B 
lymphocytes and with a subsequent distinct pattern of lym-
phocyte repopulation following treatment, which leads to a 
shift from pro- to anti-inflammatory cytokine profile [23–26]. 
Other studies have suggested that the impact of alemtuzumab 
may extend beyond its anti-inflammatory effect and include 
neuroprotection through stimulation of neurotrophin produc-
tion, which may contribute to the sustained improvements in 
disability observed over the long term [27].
Safety findings of the CAMMS223 12-year cohort were 
consistent with prior phase 2, phase 3, and extension stud-
ies [6–10, 17]. IARs were most frequent at the first alem-
tuzumab course but declined with subsequent courses. 
Overall AEs, including infections, were most prevalent in 
the first year of the study with reduced incidences in the 
extension studies compared with the core trial. Notably, life-
threatening infections, in particular Listeria monocytogenes 
or cytomegalovirus infection, were not observed in this 
12-year cohort. Thyroid AEs, the most commonly occurring 
autoimmune events, peaked in Years 2 and 3 of the core trial 
and declined thereafter, consistent with the trend seen in 
9-year analyses of patients from the phase 3 CARE-MS stud-
ies [12, 13]. In this 12-year cohort of CAMM223 patients, 
one case of ITP occurred in Year 4 (within 4 years since last 
alemtuzumab dose) with no new cases in Years 5–12. There 
were no cases of autoimmune nephropathies over 12 years. 
Five cases of thyroid AEs (including three serious events) 
were reported after 4  years since the last alemtuzumab 
course. A comprehensive risk management strategy includ-
ing physician and patient education combined with the pre-
scribed safety monitoring program has helped minimize the 
treatment risks with alemtuzumab [28, 29]. With the emer-
gence of additional AEs observed during post-marketing use 
of alemtuzumab, including those occurring shortly after infu-
sion, the European Medicines Agency (EMA) has recently 
recommended alemtuzumab to be used only in patients with 
highly active disease (despite treatment with ≥ 1 DMT) or 
rapidly worsening disease, and without certain heart, circu-
lation or bleeding disorders or autoimmune disorders other 
than MS [30]. It is worth noting that none of these new 
safety signals, including possibly infusion-related serious 
side effects or life-threatening autoimmune diseases such as 
autoimmune hepatitis and hemophagocytic lymphohistiocy-
tosis, were observed in this 12-year cohort.
The relatively small sample size of the 12-year cohort is 
a limitation of this analysis. Additionally, a selection bias 
in favor of patients with a positive experience with alem-
tuzumab has to be considered, since patients participated 
in the extension study voluntarily. However, apart from a 
slightly higher ARR, the efficacy and safety outcomes in 
patients who discontinued prior to the start of the extension 
study were largely consistent with those who remained in 
the study through 12 years, and may have minimized the 
potential for selection bias.
Conclusions
In summary, our results show that efficacy of alemtuzumab 
on clinical and MRI outcomes was maintained over 12 years 
in the long-term follow-up of a cohort of patients from the 
CAMMS223 trial who were treatment naive at study entry 
and who enrolled in extension studies. This was achieved 
with 33% of patients receiving a total of two courses of 
alemtuzumab through Year 12, and 73% receiving no more 
than three courses. The safety profile of alemtuzumab in this 
long-term follow-up cohort over the 12-year time-frame was 
consistent with other alemtuzumab clinical trials.
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